Literature DB >> 8486332

Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism.

E J Seree1, P J Pisano, M Placidi, R Rahmani, Y A Barra.   

Abstract

This report characterizes the cytochrome P450 isozyme involved in clonazepam metabolism. This study was undertaken using a library of liver microsomal fractions prepared from untreated rabbits or those treated with drugs known to specifically induce various cytochrome P450 isozymes (ie P450 2B4 by phenobarbital, P450 1A1 and P450 1A2 by 3-methylcholanthrene and beta-naphthoflavone, P450 2E1 by acetone and ethyl alcohol, and P450 3A6 by erythromycin). Only microsomes obtained from phenobarbital-treated rabbits exhibited a type II binding spectrum upon addition of clonazepam (Ks(app) = 31.4 +/- 3.8 microM) and significantly metabolized clonazepam to 7-aminoclonazepam. Benzphetamine, which is a known substrate for P450 2B1 was also extensively metabolized by microsomes prepared from phenobarbital treated rabbits. This indicates that the same isozyme (P450 2B subfamily) was involved in the biotransformation of both substrates. Experiments performed on 14 human liver microsomal preparations showed a wide interindividual variability (from 1-4) and a good correlation (r = 0.70) between benzphetamine and clonazepam metabolism. Since P450 3A4 (nf25) was involved in benzphetamine metabolism, clonazepam was probably nitroreduced by the same isozyme. An oligonucleotide specific for the P450 3A4 gene subfamily was synthetized and used for hybridization on total RNA from human liver samples. Two transcripts of 2.2 and 3.0 kb were detected and the level of the 2.2 kb mRNA expression was significantly correlated (r = 0.61) with the intensity of clonazepam nitroreduction by the corresponding microsome batches.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486332     DOI: 10.1111/j.1472-8206.1993.tb00219.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  11 in total

Review 1.  Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

2.  Identifying Metabolites of Meclonazepam by High-Resolution Mass Spectrometry Using Human Liver Microsomes, Hepatocytes, a Mouse Model, and Authentic Urine Samples.

Authors:  Svante Vikingsson; Ariane Wohlfarth; Mikael Andersson; Henrik Gréen; Markus Roman; Martin Josefsson; Fredrik C Kugelberg; Robert Kronstrand
Journal:  AAPS J       Date:  2017-01-13       Impact factor: 4.009

Review 3.  Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

Review 4.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

5.  Influence of CYP2B6 and CYP3A4 polymorphisms on the virologic and immunologic responses of patients treated with efavirenz-containing regimen.

Authors:  Yaya Kassogue; Brehima Diakite; Mamoudou Maiga; Oumar Kassogue; Issa Konate; Kadidiatou Tamboura; Fousseyni Diarra; Zoumana Diarra; Mahamadou Karamoko Sawadogo; Yaya Goita; Sidi Boula Sissoko; Adama Seydou Sissoko; Nouhoum Guirou; Hind Dehbi; Sellama Nadifi; Sekou Bah; Cheick Bougadari Traore; Bakarou Kamate; Sounkalo Dao; Guimogo Dolo
Journal:  Pharmacogenet Genomics       Date:  2022-06-22       Impact factor: 2.000

6.  Functional polymorphism of CYP2B6 G15631T is associated with hematologic and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.

Authors:  Yaya Kassogue; Meryem Quachouh; Hind Dehbi; Asma Quessar; Said Benchekroun; Sellama Nadifi
Journal:  Med Oncol       Date:  2013-11-29       Impact factor: 3.064

Review 7.  Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation.

Authors:  Chantal Schlatter; Sabin S Egger; Lydia Tchambaz; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 8.  Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.

Authors:  Alan L Myers; Jitesh D Kawedia; Richard E Champlin; Mark A Kramer; Yago Nieto; Romi Ghose; Borje S Andersson
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-08-17       Impact factor: 4.481

9.  Optimization of Clonazepam Therapy Adjusted to Patient's CYP3A Status and NAT2 Genotype.

Authors:  Katalin Tóth; Gábor Csukly; Dávid Sirok; Ales Belic; Ádám Kiss; Edit Háfra; Máté Déri; Ádám Menus; István Bitter; Katalin Monostory
Journal:  Int J Neuropsychopharmacol       Date:  2016-12-30       Impact factor: 5.176

10.  A serious adverse drug reaction probably induced by clonazepam: a case report of myotoxicity.

Authors:  Xiaonian Han; Jinping Wang
Journal:  BMC Pharmacol Toxicol       Date:  2019-11-05       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.